ArticleJournal of contemporary brachytherapy2021

Eligibility criteria according to EAU/ESTRO/SIOG guidelines for exclusive iodine-125 brachytherapy for intermediate-risk prostate adenocarcinoma patients: impact on relapse-free survival.

Sophie Robin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.